MRUS (Merus NV) Change In Inventory : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Merus NV Change In Inventory?

Merus NV's change in inventory for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Merus NV's inventory stayed the same from Jun. 2024 to Sep. 2024 .

Merus NV's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Merus NV's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Merus NV's Total Inventories for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Merus NV's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.00.

Merus NV Change In Inventory Historical Data

The historical data trend for Merus NV's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Change In Inventory Chart

Merus NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Merus NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Merus NV Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Merus NV (NAS:MRUS) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Merus NV's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Merus NV's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Merus NV's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	11.772
	=	0.00

Merus NV Change In Inventory Related Terms

Thank you for viewing the detailed overview of Merus NV's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Merus NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

2GH:Germany

Address

Uppsalalaan 17, Utrecht, NLD, 3584 CT

Website

https://www.merus.nl

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Executives

Harry Shuman	officer: Chief Accounting Officer	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman	officer: EVP & General Counsel	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg	director, officer: President, CEO & PFO	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De	officer: Chief Technology Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy	director	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen	director
Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki	director	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry	director	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W	officer: SVP & Chief Scientific Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe	officer: SVP, CMO	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby	officer: EVP & Chief Scientific Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM